TRIPAWDS: Home to 20086 Members and 2005 Blogs.

Cisplatin biodegradeable beads save Gretta from amputation

gretta cancer dog cisplatin beadsLast summer, our friend Jami told us about about “cisplatin biodegradeable beads,” an experimental type of chemotherapy treatment being tested in dogs with bone cancer, who are undergoing limb-sparing procedures instead of amputation.

These biodegradeable beads are being implanted at the time of the limb-sparing surgery, with the goal of preventing tumor regrowth in the leg, through a gradual release of cisplatin, a chemotherapy drug. This type of treatment can possibly reduce the recurrence of tumors in dogs who have had limb-sparing surgery instead of an amputation. An article in the Annals of Surgical Oncology describes the treatment.

Jami wrote to tell us about her dog, Miss Gretta, who underwent the implant surgery at age 12. Jamie has generously offered to explain the procedure, and wanted to share Gretta’s progress with Tripawds.

Read more.

Tripawd News: Clinical Trial Tests New Treatment Drug

maf_ccc.jpgThis article first appeared in:

Animal News
The Morris Animal Foundation

Vol. 7, Issue 4

Written by Heidi Jeter

“Osteosarcoma.” Greyhound lovers are all too familiar with this dreaded word. For yet unknown reasons, this beloved breed is highly susceptible to bone cancer. Unfortunately, treatment options haven’t changed much in the past 20 years. The good news, though, is that new therapies lie on the horizon. In a current clinical trial, scientists are evaluating an already available drug to determine its effectiveness in helping dogs diagnosed with bone cancer, including greyhounds.

The clinical trial is part of Morris Animal Foundation’s (MAF) recently launched Canine Cancer Campaign, whose goal is to cure canine cancer within a dog’s lifetime – the next 10 to 20 years. World-renown scientists will work together on MAF-funded research projects that will lead to breakthroughs in prevention and treatment for dogs with cancer.

“One in four dogs will die of cancer and half of all dogs will suffer from it,” says Dr. Patricia N. Olson, president/CEO of MAF. “This clinical trial is part of a large-scale effort to encourage collaboration on a national level to address this serious health problem.”

Read more.

Tripawds is brought to you by Tripawds.